...
首页> 外文期刊>Analytical chemistry >High-Throughput Method Development for Sensitive, Accurate, and Reproducible Quantification of Therapeutic Monoclonal Antibodies in Tissues Using Orthogonal Array Optimization and Nano Liquid Chromatography/Selected Reaction Monitoring Mass Spectrometry
【24h】

High-Throughput Method Development for Sensitive, Accurate, and Reproducible Quantification of Therapeutic Monoclonal Antibodies in Tissues Using Orthogonal Array Optimization and Nano Liquid Chromatography/Selected Reaction Monitoring Mass Spectrometry

机译:利用正交阵列优化和纳米液相色谱/选择反应监测质谱技术开发高通量方法,以对组织中的治疗性单克隆抗体进行灵敏,准确和可重复的定量

获取原文
获取原文并翻译 | 示例
           

摘要

Although liquid chromatography/mass spectrometry using selected reaction monitoring (LC/SRM-MS) holds great promise for targeted protein analysis, quantification of therapeutic monoclonal antibody (mAb) in tissues represents a daunting challenge due to the extremely low tissue levels, complexity of tissue matrixes, and the absence of an efficient strategy to develop an optimal LC/SRM-MS method. Here we describe a high-throughput, streamlined strategy for the development of sensitive, selective, and reliable quantitative methods of mAb in tissue matrixes. A sensitive nano-LCanospray-MS method was employed to achieve a low lower limit of quantification (LOQ). For selection of signature peptides (SP), the SP candidates were identified by a high-resolution Orbitrap and then optimal SRM conditions for each candidate were obtained using a high-throughput, on-the-fly orthogonal array optimization (OAO) strategy, which is capable of optimizing a large set of SP candidates within a single nano-LC/SRM-MS run. Using the optimized conditions, the candidates were experimentally evaluated for both sensitivity and stability in the target matrixes, and SP selection was based on the results of the evaluation. Two unique SP, respectively from the light and heavy chain, were chosen for quantification of each mAb. The use of two SP improves the quantitative reliability by gauging possible degradation/modification of the mAb. Standard mAb proteins with verified purities were utilized for calibration curves, to prevent the quantitative biases that may otherwise occur when synthesized peptides were used as calibrators. We showed a proof of concept by rapidly developing sensitive nano-LC/SRM-MS methods for quantifying two mAb (8c2 and cT84.66) in multiple preclinical tissues. High sensitivity was achieved for both mAb with LOQ ranged from 0.156 to 0.312 (mu)g/g across different tissues, and the overall procedure showed a wide dynamic range (>=500-fold) and good accuracy [relative error (RE) < 18.8percent] and precision [interbatch relative standard deviation (RSD) < 18.1percent, intrabatch RSD < 17.2percent]. The quantitative method was applied to a comprehensive investigation of the steady-state tissue distribution of 8c2 in wild-type mice versus those deficient in FcRn alpha-chain, Fc(gamma)IIb, and Fc(gamma)RI/Fc(gamma)RIII, following a chronic dosing regimen. This work represents the first extensive quantification of mAb in tissues by an LC/MS-based method.
机译:尽管使用选择的反应监测(LC / SRM-MS)的液相色谱/质谱法对靶向蛋白质分析具有广阔的前景,但由于组织水平极低,组织复杂,定量治疗组织中的单克隆抗体(mAb)仍是一项艰巨的挑战。矩阵,缺乏开发最佳LC / SRM-MS方法的有效策略。在这里,我们描述了一种高通量,简化的策略,用于开发组织基质中mAb的灵敏,选择性和可靠的定量方法。采用灵敏的纳米LC /纳米喷雾MS方法获得较低的定量下限(LOQ)。为了选择特征肽(SP),可通过高分辨率Orbitrap识别SP候选物,然后使用高通量,动态的正交阵列优化(OAO)策略获得每个候选物的最佳SRM条件。能够在单个nano-LC / SRM-MS运行中优化大量SP候选对象。使用优化的条件,通过实验评估了候选物在目标基质中的敏感性和稳定性,并且SP的选择基于评估的结果。选择了分别来自轻链和重链的两个独特的SP来定量每个mAb。通过测量mAb可能的降解/修饰,两个SP的使用可提高定量可靠性。将纯度经过验证的标准mAb蛋白用于校正曲线,以防止使用合成肽作为校正剂时可能出现的定量偏差。我们通过快速开发灵敏的纳米LC / SRM-MS方法来量化多个临床前组织中的两个mAb(8c2和cT84.66),从而显示了概念验证。两种单克隆抗体在不同组织中的LOQ范围均为0.156至0.312μg/ g,均获得了高灵敏度,整个过程显示出较宽的动态范围(> = 500倍)和良好的准确度[相对误差(RE)< 18.8%]和精度[批间相对标准偏差(RSD)<18.1%,批内RSD <17.2%]。定量方法应用于综合研究8c2在野生型小鼠与FcRnα链,FcγIIb和FcγRI/FcγRIII缺乏的小鼠中的稳态组织分布,遵循长期服药方案。这项工作代表了通过基于LC / MS的方法对组织中mAb的首次广泛定量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号